Viladrich P F, Cabellos C, Pallares R, Tubau F, Martínez-Lacasa J, Liñares J, Gudiol F
Infectious Diseases Service, University of Barcelona, Spain.
Antimicrob Agents Chemother. 1996 Jan;40(1):218-20. doi: 10.1128/AAC.40.1.218.
We treated nine patients (10 episodes) with meningitis caused by Streptococcus pneumoniae isolates with decreased susceptibilities to broad-spectrum cephalosporins with high doses of cefotaxime (300 mg/kg of body weight per day; maximum dose, 24 g/day). Early adjunctive therapy with dexamethasone was also administered. Cefotaxime MICs were 0.5 (three episodes), 1 (five episodes), and 2 (two episodes) micrograms/ml, and MBCs ranged from 1 to 4 micrograms/ml. Therapy was well tolerated, and all patients experienced prompt clinical improvement. One patient died 8 days after the end of therapy, the central nervous system infection had already been cured, and the remaining patients recovered without relapses.
我们用大剂量头孢噻肟（每日300mg/kg体重；最大剂量24g/天）治疗了9例（10个疗程）由对广谱头孢菌素敏感性降低的肺炎链球菌分离株引起脑膜炎患者。同时还给予了地塞米松进行早期辅助治疗。头孢噻肟的最低抑菌浓度（MIC）为0.5μg/ml（3个疗程）、1μg/ml（5个疗程）和2μg/ml（2个疗程），最低杀菌浓度（MBC）为1至4μg/ml。治疗耐受性良好，所有患者临床症状均迅速改善。1例患者在治疗结束8天后死亡，其中枢神经系统感染已治愈，其余患者均康复且无复发。
